BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

761 related articles for article (PubMed ID: 17122725)

  • 1. Review of progressive multifocal leukoencephalopathy and natalizumab.
    Aksamit AJ
    Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions.
    Stüve O; Marra CM; Cravens PD; Singh MP; Hu W; Lovett-Racke A; Monson NL; Phillips JT; Tervaert JW; Nash RA; Hartung HP; Kieseier BC; Racke MM; Frohman EM; Hemmer B
    Arch Neurol; 2007 Feb; 64(2):169-76. PubMed ID: 17296831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A giant MS plaque mimicking PML during natalizumab treatment.
    Twyman C; Berger JR
    J Neurol Sci; 2010 Apr; 291(1-2):110-3. PubMed ID: 20144466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
    Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F
    Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
    Wenning W; Haghikia A; Laubenberger J; Clifford DB; Behrens PF; Chan A; Gold R
    N Engl J Med; 2009 Sep; 361(11):1075-80. PubMed ID: 19741228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
    Lindå H; von Heijne A; Major EO; Ryschkewitsch C; Berg J; Olsson T; Martin C
    N Engl J Med; 2009 Sep; 361(11):1081-7. PubMed ID: 19741229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
    Sørensen PS; Bertolotto A; Edan G; Giovannoni G; Gold R; Havrdova E; Kappos L; Kieseier BC; Montalban X; Olsson T
    Mult Scler; 2012 Feb; 18(2):143-52. PubMed ID: 22312009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive multifocal leukoencephalopathy.
    Weissert R
    J Neuroimmunol; 2011 Feb; 231(1-2):73-7. PubMed ID: 20937530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.
    Langer-Gould A; Atlas SW; Green AJ; Bollen AW; Pelletier D
    N Engl J Med; 2005 Jul; 353(4):375-81. PubMed ID: 15947078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple sclerosis, natalizumab, and PML: helping patients decide.
    Rudick RA
    Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S18-23. PubMed ID: 22123928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
    Baldwin KJ; Hogg JP
    Curr Opin Neurol; 2013 Jun; 26(3):318-23. PubMed ID: 23493158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.
    Schröder A; Lee DH; Hellwig K; Lukas C; Linker RA; Gold R
    Arch Neurol; 2010 Nov; 67(11):1391-4. PubMed ID: 20625069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
    Boster AL; Nicholas JA; Topalli I; Kisanuki YY; Pei W; Morgan-Followell B; Kirsch CF; Racke MK; Pitt D
    JAMA Neurol; 2013 Mar; 70(3):398-402. PubMed ID: 23338729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the management of PML: focus on natalizumab.
    Fox R
    Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S33-7. PubMed ID: 22123933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.
    Kleinschmidt-DeMasters BK; Tyler KL
    N Engl J Med; 2005 Jul; 353(4):369-74. PubMed ID: 15947079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases.
    Boren EJ; Cheema GS; Naguwa SM; Ansari AA; Gershwin ME
    J Autoimmun; 2008; 30(1-2):90-8. PubMed ID: 18191544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early changes on electroencephalography in natalizumab-associated progressive multifocal leucoencephalopathy.
    Kleiter I; Schröder M; Lürding R; Schuierer G; Clifford DB; Bogdahn U; Steinbrecher A; Pöschl P
    Mult Scler; 2010 Jun; 16(6):749-53. PubMed ID: 20453014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.
    Yousry TA; Pelletier D; Cadavid D; Gass A; Richert ND; Radue EW; Filippi M
    Ann Neurol; 2012 Nov; 72(5):779-87. PubMed ID: 23280794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.
    Hunt D; Giovannoni G
    Pract Neurol; 2012 Feb; 12(1):25-35. PubMed ID: 22258169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.